Chemotherapeutical treatment of basal cell carcinoma with bleomycin via microinfusion of the drug into the skin (MMP®)^☆

Abstract

Background

Bleomycin is a chemotherapeutical drug used to treat several neoplasias, including non-melanoma skin cancer; it is effective in the treatment of basal cell carcinoma (BCC) via intralesional infiltration. Transdermal drug delivery, which includes technologies such as CO₂ Laser, Dermapen, Dermaroller and MMP®, delivers the desired medication to treat skin neoplasias and also acts in skin rejuvenation.

Objective

To treat BCC lesions using bleomycin via MMP®.

Methods

Ninety-eight BCC lesions in different anatomical areas were treated using MMP® technology to administer and uniformly distribute bleomycin throughout the lesion and in the established safety margin.

Results

The cure rate after six months was 96.94%; and recurrences were not associated with lesion size and/or depth. Adverse effects were the expected ones.

Study limitations

The follow-up time was only six months.

Conclusion

This therapeutic route showed to be promising and effective.

Keywords
Bleomycin; Carcinoma, basal cell; Drug therapy; Skin neoplasms; Therapeutics